ARTELO BIOSCIENCES, INC. Derivative, Gain (Loss) on Derivative, Net
ARTELO BIOSCIENCES, INC. (ARTL) reported Derivative, Gain (Loss) on Derivative, Net of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2026-08-12
- ARTELO BIOSCIENCES, INC. derivative, gain (loss) on derivative, net for the quarter ending 2026-06-30 was $0.00.
- ARTELO BIOSCIENCES, INC. derivative, gain (loss) on derivative, net for the quarter ending 2026-03-31 was -$146.00K.
- ARTELO BIOSCIENCES, INC. derivative, gain (loss) on derivative, net for the quarter ending 2025-12-31 was -$137.00K.
- ARTELO BIOSCIENCES, INC. derivative, gain (loss) on derivative, net for the quarter ending 2025-09-30 was $75.00K.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | -$146.00K 10-Q · filed 2026-08-12 | -$283.00K derived: sum of 3 quarters · filed 2026-08-12 | -$208.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$146.00K 10-Q · filed 2026-05-14 | -$283.00K derived: sum of 2 quarters · filed 2026-05-14 | -$208.00K derived: sum of 3 quarters · filed 2026-05-14 | -$208.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$137.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$62.00K derived: sum of 2 quarters · filed 2026-03-17 | -$62.00K derived: sum of 3 quarters · filed 2026-08-12 | -$62.00K 8-K · filed 2026-03-17 |
| 2025-09-30 | $75.00K 10-Q · filed 2025-11-12 | $75.00K derived: sum of 2 quarters · filed 2026-08-12 | $75.00K 10-Q · filed 2025-11-12 | $75.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 8-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |